stonks4u
Sign up free
PLSE logo

PLSE Pulse Biosciences, Inc.

NASDAQ Capital Market · Medical - Instruments & Supplies · Healthcare

$44.54
-0.38 (-0.85%)

Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively el…

Market Cap: $3.08Bwww.pulsebiosciences.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

100
100
Aug 16Aug 16

Quote

Day Range
$43.75 – $45.20
52-Week Range
$12.56 – $46.97
Volume
$398.6K
Market Cap
$3.08B
50-Day Avg
$30.81
200-Day Avg
$21.55
Prev Close
$44.92
Open
$44.50

Valuation & Ratios

P/E Ratio
-12.71
EPS
$-1.08
P/B Ratio
11.47
P/S Ratio
2643.82
Debt/Equity
0.09
Current Ratio
10.53
Dividend Yield
+0.0%
Gross Margin
-360.0%

Returns & Efficiency

Return on Equity
-90.2%
Return on Assets
-75.7%
FCF Yield
-5.9%
EV/EBITDA
-11.88

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$350.0K$-72.78M$-1.08
2024$0.00$-53.59M$-0.92
2023$0.00$-42.21M$-0.88
2022$700.0K$-58.51M$-1.72
2021$1.42M$-63.66M$-2.28

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Wed, Nov 4(in 3 months)

Consensus estimate $-0.35 per share

4of 6 quarters beat consensus

Typical surprise +4.2% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, Aug 6$-0.36 vs $-0.29miss
  • Mon, May 4$-0.27 vs $-0.32beat
  • Thu, Feb 19$-0.26 vs $-0.27beat
  • Wed, Nov 5$-0.29 vs $-0.31beat
  • Tue, Aug 12$-0.28 vs $-0.26miss
  • Thu, Mar 27$-0.17 vs $-0.24beat

Estimates and results for PLSE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by PLSE officers and directors.

Bought
$31.3m

10 trades

Sold
$6.6m

18 trades

  • Duggan Robert Wbought
    director, 10 percent owner:·660,233 @ $19.69·$13.0m·May 11, 2026·filing
  • Laviolette Paul Abought
    director, officer: Chief Executive Officer·15,000 @ $19.69·$295k·May 11, 2026·filing
  • Laviolette Paul Abought
    director, officer: Chief Executive Officer·15,000 @ $19.69·$295k·May 11, 2026·filing
  • Duggan Robert Wbought
    director, 10 percent owner:·660,233 @ $19.69·$13.0m·May 11, 2026·filing
  • Danahy Kevin Patricksold
    Chief Commercial Officer·5,000 @ $23.64·$118k·Feb 18, 2026·filing
  • Danahy Kevin Patricksold
    Chief Commercial Officer·20,000 @ $23.63·$473k·Feb 17, 2026·filing
  • Danahy Kevin Patricksold
    Chief Commercial Officer·20,000 @ $23.53·$471k·Feb 13, 2026·filing
  • Danahy Kevin Patricksold
    Chief Commercial Officer·20,000 @ $23.37·$467k·Feb 12, 2026·filing

72 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

PLSEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsmarketbeat.com·6h ago·Neutral

    Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform Pulse Biosciences NASDAQ: PLSE is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Conference.

    View source ↗